This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CSL-123, HCV Vaccine (w/CSL Ltd.), ISCOMATRIX
Description: CSL-123 is a vaccine based on the recombinant HCV core antigen and CSL's ISCOMATRIX adjuvant to prime Tc1-like CTL response, for the potential treatment of hepatitis C virus (HCV) infection.
Deal Structure: CSL-123 was originally developed by Chiron.
In January 2004, Chiron announced a new collaboration agreement with CSL Limited to develop a therapeutic hepatitis C vaccine. Under the terms of the joint development agreement, Chiron will provide its novel hepatitis C virus (HCV) antigens, and CSL will contribute its proprietary ISCOMATRIX adjuvant technology.
In April 2006, Novartis announced that shareholders of Chiron Corporation voted to approve its acquisition of Chiron. Under the terms of the transaction, which closed on April 20, Novartis acquired all outstanding shares of Chiron that Novartis does not already own for USD 48 per share. The all-cash deal represents a total value of USD 5.4 billion.
Partners: CSL Limited
Additional information available to subscribers only: